Microglia-targeted candidates push the Alzheimer drug envelope
Nature Reviews Drug Discovery 17, 303 (2018).
doi:10.1038/nrd.2018.65
Author: Asher Mullard
Denali Therapeutics is taking a swing at neuroinflammation with a first-in-man trial of a RIPK1 inhibitor, while the company and others search for ways to target microglial biology more precisely.
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research